Data Complexities with the EU UDI Regime

Add bookmark

Download Your Copy

We respect your privacy, by clicking "Download Your Copy" you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object . In addition, you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data click here. You can unsubscribe at any time.

As the US ploughs ahead with its UDI regime, the EU’s launch of Medical Device Regulation (MDR) draft documents last year helped progress industry understanding. However, a lot of uncertainty remains regarding the European UDI landscape. On average, a selection of experts have highlighted one key hurdle the market should brace for: data management with the EU UDI regime. Due to this area being expected to differ from the FDA’s GUDID process quite sharply in some places. 

With the MDR due to come into effect in a few years time, Pharma IQ gains insight on the forecasted data complexities attached to the EU’s UDI gameplan.

The Line up

  • State Of Play
  • UDI at a Glance
  • Considerations
  • for the database
  • Approaching the EU UDI data
  • complexities.
  • Final remarks
  • Reserve Your Place Today - UDI & Traceability Forum
  • Resources


Have Your Say
Rate this feature and give us your feedback in the comments section below